This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
An important aspect of the immune system’s protective power is its ability to tell the difference between “self” and “non-self” cells. However, in cancer this line between normal, healthy cells and tumor cells becomes blurred and sometimes allows tumors to escape immune recognition. Therefore, Dr. Megan Ruhland aims to advance our understanding of this process so that we can develop ways to address it. Specifically, her team has developed a model that will allow her to track immune cells and their engagements during normal tissue homeostasis as well as during the development of lung cancer. This knowledge could then provide new targets for immunotherapy that enable the immune system to reject tumors in the same way it eliminates invaders like viruses or bacteria.
University of California, San Francisco | All Cancers | 2017 | Matthew F. Krummel, Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
A recent diabetes-related discovery by CRI Lloyd J. Old STAR Dr. Andrea Schietinger has promising implications for cancer immunotherapy
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.